Unsaturated cobalamin-binding capacity in plasma (P-UBBC) is determined by use of a silica gel (QUSO G32) to separate haptocorrin (P-ApoHC) and transcobalamin (PAp0TC). The method is sensitive and precise: detection limit 13 pmol/L, interassay coefficients of variation 3% for P-UBBC (mean = 1080 pmol/L), 4% for P-Ap0TC (mean = 700 pmol/L) (n = 30). Values for P-UBBC, P-Ap0HC, P-Ap0TC, and P-TBBC (P-UBBC plus P-cobalamin) determined in a population study of 228 invidivuals, ages 21-87 years, did not differ by sex. These values increased with age, whereas the cobalamin saturation (P-cobalamin as percentage of P-TBBC) decreasedwith age. However, these changes were statistically significant but marginal and thus not clinically important. We therefore suggest using combined reference intervals (central 95 percentiles) for all age groups: 500-1200 pmol/L for P-UBBC, 90-275 pmol/L for P-Ap0HC, 400-930 pmol/L for P-ApoTC, 850-1600 pmol/L for P-TBBC, and 20-50% for cobalamin saturation. Results for 277 inpatients show high P-Ap0HC in myeloproliferative disorders or acute nonlymphatic leukemia, whereas P-Ap0TC concentrations are high in some patients with lymphoproliferative disorders or autoimmune diseases. The latter is responsible for the transport of cobalamins into cells, whereas the function of the former is virtuallyunknown (1). Both proteins circulate in blood partly saturated (holo-) and partly unsaturated (apo-) with cobalamin. The clinical importance of determining the concentration of these proteins in plasma has been a subject of increasing interest during the last decades.
ence group comprised 228 persons, 121 men and 107 women, ages 21-87 years, who were participating in a population survey (The Copenhagen City Heart Study).
Study sample of hospitalized patients. We also studied a group of 277 patients, 150 men and 127 women, ages 10-92 years (mean 60.5), who had been referred to the department of internal medicine and hematology as unpatients or as outpatients of the ambulatory care unit during a fouryear period. The patients could be divided into five diagnostic groups:
#{149}35 patients had anemia-seven with treated and 14 with untreated perniciousanemia, and 14 with folate deficiency, iron deficiency, hemolysis, or anemia due to chronic infections; #{149}56 patients with myeloproliferatiue disorders-43 were as yet untreated for polycythemia (n = 23), chronic myelogenous leukemia (n = 9), primary myelofibrosis (ii = 8), or essential thrombocytosis (n = 1), and 13 were being treated for these diseases; #{149}72 patients with lymphoproliferatiue disorders-30 were as yet untreated for chronic lymphocytic leukemia (n = 10), non-Hodgkin's malignant lymphoma (n = 7), Hodgkin's disease (n = 4), multiple myeloma (n = 4), hairy cell leukemia (n = 1), WaldenstrOm's macroglobulinemia (n = 1), acute lymphoblastic leukemia (ii = 1), prolymphocytic leukemia (n = 1), and angioimmunoblastoma (n = 1), whereas 42 were being treated for chronic lymphocytic leukemia (n = 8), non-Hodgkin's malignant lymphoma (n = 9), Hodgkin's disease (ii = 8), multiple myeloma (n = 7), hairy cell leukemia (n = 1), WaldenstrOm's macroglobulinemia (n = 1), acute lymphoblastic leukemia (n = 8);
#{149}33 patients with acute nonlymphocytic leukemio,-27 untreated, of whom eight had had a previous myelodysplastic syndrome, and sixwho were receiving treatment;
. Preparation of samples. Plasma was prepared by centrifuging EDTA-treated blood within 2 h aftersampling and kept frozen at -20 #{176}C until analysis.
P-ApoHC and P-ApoTC by separating on silica gel. We used a modification of the method of Jacob and Herbert (10) as previously described (18) . All specimens containing >1200 pmoIJL were appropriately diluted with 0.15 mol/L NaC1 and re-analyzed.
The silica gel was QUSO G32 (obtained from Bie and Berntsen Ltd., R#{248}dovre, Denmark).
Plasma cobalamin (P-cobalamin).
We quantified P-cobalamin in 216 specimens obtained from the reference group, with use of pure intrinsic factor as the binder (19) . P-TBBC and cobalamin saturation. P-TBBC was calculated as the sum of P-UBBC and P-cobalamin from each specimen; cobalamin saturation indicated the fraction that the P-cobalamin was of P-TBBC.
Statistical methods. We used standard parametric and nonparametric statistical tests as indicated later in the text. 
Results

Reliability of the QUSO G32 Method
Charcoal precipitation of cyano[57Colcobalamin-labeled plasma combined with QUSO G32 was used to determine the P-UBBC and P-ApoTC (adsorbed to QUSO G32). PApoHC was calculated as the difference between P-UBBC and P-ApoTC.
In EDTA-stabilized pooled plasma kept at -20 #{176}C for up to 12 months, we could demonstrate no time-related change in the P-ApoHC or P-Ap0TC (P >0.5, n = 60).
The results for serial dilutions of P-UBBC with 0.15 molIL NaC1 to give concentrations in the range of 13 to 1250 pmolIL fell on a straight line (P 0.0001). P-ApoTC could be detected when it constituted at least 0.5% of P-UBBC. The detection limit, defined as twice the SD at low concentrations, for the absolute amount of P-UBBC, P-ApoHC, and P-ApoTC was 13 pmolfL.
Analysis of pooled plasma 30 times during sixmonths showed interassay coefficients of variation (CVs) of 3% for P-UBBC and 4% for P-ApoTC at mean respective concentrations of 1082 and 700 pmolIL. Intra-assay CVs were 2% for both P-UBBC and P-ApoTC. The CV was also 3% for P-UBBC [5069 pmollL (mean)J in plasma with a high content of P-ApoHC (from patients with chronic myelogenous leukemia whose P-ApoHC concentrations were about 5000 pmoIJL). The CV for P-ApoTC was 15% at 605 pmol/L in plasma from patients with chronic myelogenous leukemia, in whom the P-ApoTC constituted between 11% and 23% of the P-UBBC (n = 10).
intra-Individual Variation
Two healthy volunteershad blood sampled every week for 10 weeks. CVs were 4.2-12% for mean (and SD) PApoHC concentrations of 150(10.3) and 178(7.7) pmol/L, anU for P-ApoTC of 585(73.6) and 801(33.6) pmol/L.
Interindividual Variation
Reference population.
The interindividual variation of these analyses in the 228 individuals in the reference population, expressed as CV, was 27% for P-ApoTC (627, SD 139.6, pmolJL) and 32% for P-Ap0HC (168, SD 54.0, pmolIL). For P-UBBC, P-ApoTC, P-ApoHC, and P-TBBC the concentrations significantly increased with age (P <0.001, Spearman rank correlation, p = 0.35,0.38,0.31, and 0.28, respectively). No sex-related difference could be demonstrated for P-UBBC, P-ApoTC, P-ApoHC, or TBBC, either for the population as a whole or divided into age decades (P >0.2). The observed ranges of values as a function of age are shown in Figure 1 and Table 1 .
The cobalanun saturation significantly decreased with age (P <0.0001, Spearman rank correlation, p = -0.29) (Figure  1) , again,with no significant sex-related difference (P >0.35). The age-related rangesobservedareindicated in Table 1 .
Patients. The distribution of results for the 277 patients is shown in Figure 2 . More than half of the patients with myeloproliferative disorders had increased P-ApoHC and, within this group, all patients with chronic myelogenous leukemia had increased P-Ap0HC. About a third of the patients with acute nonlymphocytic leukemia had high PApoHC, and a sixth had high P-ApoTC. The lymphoproliferative disorders showed a more variable picture, with about a fourth having increased P-ApoTC. In comparison, in the remaining patients, values were between 6% and 16% below or above the reference limits, with no characteristic diagnoses accompanying the data points outside the reference limits.
Discussion
Here we have evaluated a method for quantifying P-UBBC, P-ApoTC, and P-ApoHC (10) , and found it to be precise and easy to use for analyzing a large number of 55w. samples. The method involves a direct estimation of PApoTC and an indirect quantification of P-ApoHC. We used samples from a large, unselected group of persons for the determination of reference intervals.-a justifiable approach because major disturbances in the cobalaniin-binding proteins are relatively rare. As shown, we found no difference in the values obtained for male and female individuals, either in the whole population examined, or in those younger than 50 years. Previous studies (20) (21) (22) have indicated that values for P-UBBC and PApoTC were higher in women than in men (younger than 50 years). In the largest of the studies (22) , care was taken to ensure that the women were not pregnant and did not receive oral contraceptives, which are known to decrease P-UBBC (23, 24) . In the present study, we did not have information on how large a proportion of the women were taking oral contraceptives.
Cobalamin-binding proteins present in human plasma are partly saturated with cobalamin (Ho1oTC and Holo-HC). This part of the proteins, quantified as P-cobalamin, was found (25) to decrease with age in the same population as we examined. The median value of P-cobalamin decreasesby 65 pmol/L from age 20 to age 80. Over the same age span, P-ApoTC and P-ApoHC increaseby 140 and 60 pmolIL, respectively, and the increase in P-TBBC is about 180 pmol/L. Whether this increase in the cobalaminbinding proteins in plasma with age indicates increased synthesis or decreased elimination is unknown. Although the increasein P-ApoTC and P-ApoHC with age is highly significant, the absolute changes with age are marginal. Therefore we do not recommend use of agerelated reference intervals for daily routine.
In the present study we were able to calculate the cobalamin saturation. The possible clinical importance of the cobalainin saturation of plasma in the diagnosis of a cobalamin-deficiency state remains to be proven.
Our results are important for the interpretation of the previous results concerningP-cobalamin (25) . As we have shown here, the decrease of P-cobalainin with age is not induced by a decrease in the cobalamin-binding proteins, because P-ApoHC, P-ApoTC, and P-TBBC all increase with age. This observation reinforces the questions of whether the elderly have a suboptimal concentration of P-cobalamin, and if so, whether thisimplies a latent cobalaniin deficiency. Available data do not support the idea that elderly people with relatively low P-cobalamin have functional cobalamin deficiency. However, little is known concerning the natural history of persons with low P-cobalamin, and it is uncertain how many will eventually developcobalamin deficiency.
As we saw, interindividual variation in the concentration of the cobalamin-binding proteins is small. Thus determination of the cobalamin-binding proteins may be potentially useful in the diagnosis and prognosis of various disorders. Also, because intra-individual variation is small, at least in healthy persons, the cobalamin-binding proteins in plasma may serve as "markers" of disease activity. The present paper confirms that quantification of the cobalamin-binding proteins may be of potential use in cases of myeloproliferative disorders (26) and acute nonlyniphocytic leukemia, in which concentrations of haptocorrin are increased, and in lymphoproliferative and autoimmune disorders (17, 27) , in which concentrations of transcobalamin are increased. Our paper emphasizes that only a few patients with other diseases have concentrations of haptocorrin or transcobalamin outside the reference intervals. The increase in haptocorrin or transcobalamin is in most cases sufficiently pronounced to be reflected in an increased P-UBBC. However, longitudinal investigations of patients with the above-mentioned disorders are needed to decide whether quantification of P-UBBC alone is suitable for the clinical use of determinations of cobalamin-binding proteins in plasma.
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